Thomas W. P. Friedl
YOU?
Author Swipe
View article: The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors Open
Background Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on ove…
View article: Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer Open
Current aftercare after early breast cancer overlooks recent evidence on circulating free tumor DNA (ctDNA). In this case report, we present a patient with low-risk hormone-receptor-positive breast cancer. ctDNA was first detected using a …
View article: Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Methods 1
View article: Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 6: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) between HER2-positive/hormone re…
View article: Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 1. Diagram showing patient disposition.
View article: Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Purpose:The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different …
View article: Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 1. Clinical trials, multicenter studies, and institutions/centers that provided data sets from MBC patients for the pooled analysis.
View article: Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 3: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for HER2-positive/hormone receptor-positive tumors(A, B) and HER2-positive/hormone receptor-negative tumors(C, D). Survival time is giv…
View article: Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 7. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with hormone receptor-positive/HER2-negativ…
View article: Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according …
View article: Supplementary Table S8 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S8 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 8. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with HER2-positive/ hormone receptor-positi…
View article: Supplementary Figure S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 4. Kaplan-Meier plot of overall survival according to change in CTC status from baseline to first follow-up (cutoff for CTC positivity ≥1 CTC). (A) HER2-positive/hormone receptor-positive tumors; (B) HER2-positive/horm…
View article: Supplementary Table S5 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S5 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 5: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) among tumor subtypes (hormone re…
View article: Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 2: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for a cutoff for CTC positivity ≥1 CTC (A, B, C) and a cutoff for CTC positivity ≥5 CTCs (D, E, F). Survival time is given as time sinc…
View article: Supplementary Table S9 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S9 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 9. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients that received chemotherapy-based or endocri…
View article: Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 3: Comparisons of the probabilities of being CTC positive among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to time point of CTC assessment (baseline, first follow-…
View article: Supplementary Table S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 4: Comparisons of the probabilities of being CTC positive betweenHER2- positive/hormone receptor-positive and HER2-positive/hormone receptor-negative tumors according to time point of CTC assessment (baseline, first fol…
View article: Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients
Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients Open
Circulating tumor cells (CTCs) can serve as a liquid biopsy to gain insight into treatment responses and metastatic recurrence. Due to their rarity, the analysis of CTCs is challenging and commonly based on immunomagnetic technologies usin…
View article: Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer
Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer Open
Background: The anti-tumor response of the immune system is pivotal for treating triple-negative breast cancer (TNBC), particularly as targeted therapies are limited. However, the impact of immune-modulating factors such as the application…
View article: Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay Open
This study demonstrates the feasibility of MRD detection in EBC using a plasma-only multiomic ctDNA-based approach. Larger studies are ongoing to further validate the clinical performance of the assay and demonstrate its applications.
View article: Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Purpose: The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different…
View article: Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?
Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer? Open
Objectives: Triple-negative breast cancer (TNBC) requires chemotherapy-based systemic treatment which is usually anthracycline-based (AB). The cardiotoxicity of AB regimens is especially relevant in the elderly population. Therefore, we re…
View article: Endometrial scratching and intralipid treatment—no general recommendations
Endometrial scratching and intralipid treatment—no general recommendations Open
Objectives Endometrial scratching (ES) and/or intravenous intralipid therapy (in cases of increased uterine natural killer cells, uNKs) are still conducted in several fertility centers as “add-on” treatments in patients undergoing ART, alt…
View article: Trial and error − Outcome of breech presentation depending on birth mode and root cause analysis of severe adverse events
Trial and error − Outcome of breech presentation depending on birth mode and root cause analysis of severe adverse events Open
The failed attempt of VBB indicates significantly worse UApH without lower Apgar scores or higher transfer rate to the NICU. The likelihood of a successful VBB is 9% lower with obesity and 2.5 times higher in multiparous women. Attempting …
View article: Shorter Intervals of Antenatal Corticosteroid Administration Can Influence Short- and Long-Term Outcomes in Premature Infants
Shorter Intervals of Antenatal Corticosteroid Administration Can Influence Short- and Long-Term Outcomes in Premature Infants Open
Background: Studies examining shorter intervals between antenatal corticosteroid administration (ACS) and delivery are limited. This study analyzed effects of the timing of ACS on short-term and long-term outcomes in premature infants. Met…
View article: Changes in Endometriosis-Associated Symptoms Following Immunization against SARS-CoV-2: A Cross-Sectional Study
Changes in Endometriosis-Associated Symptoms Following Immunization against SARS-CoV-2: A Cross-Sectional Study Open
Background: There are many reports about variations in the menstrual cycle after infection with SARS-CoV-2 or vaccination against it. However, data on SARS-CoV-2 infection or vaccination-related changes in menstruation-associated endometri…
View article: Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials
Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials Open
Background Invasive lobular breast carcinomas (ILC) have different histological features compared to non-special type carcinomas (NST), but the effect of histological subtypes on survival is controversial. In this study, we compared clinic…
View article: Disturbances of menstrual cycle after immunization against SARS‐CoV‐2 and their risk factors: Cross‐sectional clinical study
Disturbances of menstrual cycle after immunization against SARS‐CoV‐2 and their risk factors: Cross‐sectional clinical study Open
Objective Abnormalities of the menstrual cycle were reported after infection with SARS‐CoV‐2 and vaccination against it, but the available data are very heterogeneous, do not reflect intermenstrual variations or regional differences, and t…
View article: Post-traumatic stress syndromes following childbirth influenced by birth mode—is an emergency cesarean section worst?
Post-traumatic stress syndromes following childbirth influenced by birth mode—is an emergency cesarean section worst? Open
View article: Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials Open